19 publications
Name | Date | Type | Actions |
---|---|---|---|
First nine months 2022 sales: €405M In line with year-end outlook |
Public releases | ||
2022 HALF YEAR RESULTS Additional information on the Group’s strategy Following the conference call organised on 15 September 2022 to present its half-year results, Vetoquinol would like to provide some additional information on the strategy implemented and its outlook. |
Public releases , Half Year Report | ||
2022 HALF YEAR RESULTS Sales: €271m (up 6.0% as reported) |
Public releases | ||
H1 2022 Sales H1 2022 Sales: €271m, up 6.1% |
Public releases | ||
Availability of the 2021 universal registration document Vetoquinol informs that it has filed its 2021 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 22th, 2022. |
Public releases | ||
Q1 2022 SALES: €135M Q1 2022 SALES: €135M |
Public releases | ||
2021 Annual results ALL FINANCIAL INDICATORS UP. |
Public releases | ||
Double-digit growth in 2021 Total Group Sales: €521 million (up 21.9% as reported) |
Public releases | ||
Vetoquinol et nippon Zenyaku Kogyo Co. ltd. signent un accord de joint-venture au Japon Vetoquinol and Nippon Zenyaku Kogyo Co., Ltd., also operating under the trade name “Zenoaq”, announced today the signature of a joint-venture agreement to develop, register and market a range of animal health products in Japan. |
Public releases | ||
September 2015 year-to-date sales up 8.7% to €251.8 million Vetoquinol sales for the first nine months of 2015 rose 8.7% to €251.8 million, boosted by a positive currency impact of €13.7 million. Organic growth for the same period came to 0.7%. |
Public releases |